Circadian or daily rhythms generated from the mammalian suprachiasmatic nuclei (SCN) of the hypothalamus can be synchronized by light and nonphotic stimuli. Whereas glutamate mediates photic information, nonphotic information can in some cases be mediated by neuropeptide Y (NPY) or serotonin. NPY or serotonin can reduce the phase-resetting effect of light or glutamate; however, the mechanisms and level of interaction of these two kinds of stimuli are unknown. Here we investigate the effect of NPY on the NMDA-induced phase shift of the hamster SCN circadian neural activity rhythm by means of single-unit recording techniques.
Circadian or daily rhythms can be synchronized to 24 hr cycles of the external environment through photic entrainment. Light has access to the hypothalamic suprachiasmatic nuclei (SCN), which functions as an endogenous circadian pacemaker in mammals, through a direct projection from retinal ganglion cells (Ebling, 1996) . Light resets circadian rhythm phase during the subjective night. The daily oscillation in the firing rate of SCN neurons that can be observed for several ϳ24 hr cycles in vitro (Gillette, 1991) provides a unique system in which to examine the effect of resetting stimuli on the circadian clock. Glutamate can reset the phase of circadian rhythms in spontaneous firing rate in the SCN in vitro in a manner similar to light (Ding et al., 1994; Shibata et al., 1994; Biello et al., 1997) . Both in vivo and in vitro studies suggest that NMDA as well as non-NMDA receptors are involved in mediation of the effect of light on the pacemaker (Colwell and Menaker, 1992; Ding et al., 1994; Shibata et al., 1994) .
A variety of modulatory pathways allow flexibility in the animal's response to light. The thalamic intergeniculate leaflet projection to the SCN uses neuropeptide Y (NPY) (Harrington, 1997) . NPY is able to reduce light-induced phase shifts, and SCN application of antiserum to NPY enhances photic phase shifts (Biello, 1995; Weber and Rea, 1997) . This effect can be measured in vitro using glutamate or light (Biello et al., 1997; Yannielli and Harrington, 2000) . However, in vivo experiments showed that microinjection of NPY into the hamster SCN after a light pulse decreased the magnitude of the phase advances, without affecting phase delays (Weber and Rea, 1997) . Also, in vitro experiments showed that, in rats, coapplication of NPY at either circadian time (CT) 14 or CT 19 actually potentiated the phase-shifting effect of NMDA (Shibata et al., 1994) .
The subtype of NPY receptor underlying NPY modulation of photic responses has not yet been investigated. The Y1 and Y5 receptors are expressed in rat SCN (Weinberg et al., 1996; Larsen and Kristensen, 1998) , whereas the Y2 receptor appears to mediate the NPY phase-resetting action during the subjective day (Golombek et al., 1996; Huhman et al., 1996) . The blocking effect of NPY on pituitary adenylate cyclase activating peptide-induced daytime phase shifts is via the Y1 and/or Y5 receptors (Harrington and Hoque, 1997), whereas in rats, the inhibitory effect of NPY on serotonergic phase is mediated by Y2 receptors (Prosser, 1998) . Y1, Y2, and Y5 receptors have been implicated in the inhibitory effects of NPY on spontaneous discharge (Liou and Albers, 1991; van den Pol et al., 1996; Cutler at al., 1998; Gribkoff et al., 1998) , as well as the NPY-induced long-term depression of glutamate-elicited EPSPs (van den Pol et al., 1996) . A selective agonist as well as antagonist for the NPY Y5 receptor has just been reported (Cabrele et al., 2000; Youngman et al., 2000) .
We report that NPY is able to block NMDA-induced phase shifts in vitro. We further report that the receptor mediating this effect is the Y5 receptor, the same receptor implicated in effects of NPY on food intake (Gerald et al., 1996; Hu et al., 1996) and seizure activity (Marsh et al., 1999) .
with a 14/10 hr light /dark schedule (lights on at 5:00 A.M.), with food and water available ad libitum. Z eitgeber time (Z T) was defined as Z T 12 being the projected time of lights off in the animal room. Hamsters were administered an overdose of halothane anesthesia and decapitated during the subjective day, in most cases between Z T 8 and Z T 10. Hypothalamic slices (500 m) containing the SC N were placed in a gas-fluid interface slice chamber (Medical Systems brain slice chamber with Haas top), continuously bathed (1 ml /min) in artificial C SF (AC SF) containing (in mM): 125.2 NaC l, 3.8 KC l, 1.2 K H 2 PO 4 , 1.8 CaCl 2 , 1 MgSO 4 , 24.8 NaHC O 3 , and 10 glucose. AC SF, pH 7.4, was supplemented with an antibiotic (50 mg / l gentamicin) and a f ungicide (2 mg / l amphotericin) and maintained at 34.5°C. Warm, humidified 95% oxygen -5% carbon dioxide was continuously provided.
Electrophysiological recordings. Extracellular single-unit activity of SCN cells was detected with glass micropipette electrodes filled with ACSF, advanced through the slice using a hydraulic microdrive. Every spontaneously firing cell with a signal distinguishable from noise was recorded. The signal was fed into an amplifier for additional amplification and filtering and was continuously monitored by an oscilloscope and audio monitor. Firing rate was analyzed using data acquisition software and a customized program for calculation of descriptive statistics. A number of experiments in each condition were recorded "blind" in which the person recording data had no knowledge of the contents of the microdrop. In the majority of the cases, only one slice was recorded from each animal, but when a second slice containing SCN was recordable, the treatment applied was different from that applied to the first slice of the same animal. A total number of 118 slices were recorded in the present study.
Drugs and treatments. Drugs were applied as a 200 nl microdrop delivered to the SCN area of the slice at least 4 hr after dissection, on the same day as slice preparation. When two drops were applied, there was an average of 5 min between drops. Recordings were performed for 6 -8 hr. All of the drugs were applied at ZT 14 the same day the slices were prepared. The recordings started the following day, 2-3 hr before ZT 30 (the projected ZT 6 of the second day in vitro) and lasted until the firing rate returned to prepeak levels in all cases. The number of slices per treatment (n) is stated in the corresponding figure or is mentioned in the text.
NMDA ( (Cabrele et al., 2000) , were generously provided by Dr. A Beck Sickinger (University of Leipzig, Leipzig, Germany). Y1/ Y5 and Y2 agonists, [Leu 31 , Pro 34 ]N PY and NPY3-36 respectively, were purchased from Sigma (St. Louis, MO). All of the NPY receptor agonists were applied the same way as NPY. The Y5 antagonist was generously provided by Dr. S. Dax (RW Johnson Pharmaceutical Research Institute, Spring House, PA). The Y5 antagonist RWJ-57926 [␣-(3-pyridylmethyl)-␤-aminotetralin-derived sulfonamide] and the Y1 antagonist BIBP 3226 (R-N2-(diphenylacetyl)-N-(4-hydroxyphenyl)-methyl-argininamide; Research Biochemicals) were prepared in ACSF (2 and 1 M final concentration, respectively), and applied in the bath from ZT 13.5 to ZT 14.5, alone or in combination with other treatments applied at ZT 14 as microdrops.
Data anal ysis. Data were initially grouped into 1 hr bins, and an ANOVA was used to determine whether any bins differed from the others. If the ANOVA indicated significant differences, data were smoothed using 1 hr running means with a 15 min lag. The zeitgeber time of the middle of the 1 hr bin with the highest mean firing rate after processing by this smoother was taken as the time of peak firing rate for that slice. Phase shifts of individual slices were measured relative to the average time of peak firing of control slices. Significant differences between groups ( p Ͻ 0.05) were determined by ANOVA followed by Dunnett's (for all vs control comparison) or StudentNewman -Keuls (for all pairwise comparison) methods when multiple comparison procedures were required. Means are reported ϮSE.
RESULTS

NMDA dose-response curve
NMDA applied at ZT 14 induced a phase delay of the firing rate activity rhythm in a dose-dependent manner (Fig. 1 A) . The time of peak of control slices (ACSF microdrop at ZT 14), measured on the second day in vitro, was in the middle of the subjective day (average ZT, 6.36 Ϯ 0.23 hr) as reported previously. NMDA induced a significant phase delay at concentrations of 10 and 100 M (2.12 Ϯ 0.16 and 2.55 Ϯ 0.3 hr, respectively), whereas concentrations of and above the millimolar range (1 and 10 mM) induced a disrupted rhythm pattern, expressed as double peaks and/or overall diminished firing rate activity. It should be noted that, although three to four slices were treated with 1 or 10 mM NMDA, only two of them in each treatment could be included in the analysis, because the peak was not significant in the ANOVA of the other recordings. Saturation of the phase-shifting response to NMDA was achieved at 100 M, which was then chosen as a working concentration for all of the following experiments, unless otherwise noted. Representative individual recordings from control and NMDA (100 M)-treated slices are shown in Figure 1 induced phase delay at concentrations as low as 0.2 M, whereas the Y2 agonist failed to block the delays at 2 M. No significant changes in the phase of the firing rate rhythm were found when the agonists were applied alone at ZT 14 (0.05 Ϯ 0.01 hr for Y1/Y5 agonist; 0.09 hr for Y2 agonist; Ϫ0.1 and Ϫ0.17 hr for the two Y5 agonists, bV5 and bU8, respectively). The Y1/Y5 and both Y5 agonists paralleled the effect of NPY even at very low concentrations, suggesting that the inhibition of photic-induced responses could be achieved through one or both of these receptors. Figure 4 shows representative recordings of 100 M NMDA, with or without different concentrations of NPY or Y5 agonist.
Effect of Y5 and Y1 antagonists on NPY blockade of NMDA-induced phase shifts
We decided to test the effect of the selective and potent Y5 antagonist RJW-57926 (McNally et al., 2000; Youngman et al., 2000) and the Y1 antagonist BIBP 3226 (Rudolf et al., 1994; Wieland et al., 1995) , applied in the bath from ZT 13.5 to ZT 14.5. At ZT 14, NMDA (100 M), alone or in combination with NPY, was applied as described previously. 
DISCUSSION
We have demonstrated that NPY can block photic phase shifts via the Y5 receptor and at some level at or beyond NMDA-receptor activation in the signal transduction cascade induced by light.
Initially, we characterized NMDA-induced phase shifts in the early subjective night (ZT 14) in the hamster SCN in vitro. NMDA induced a phase delay of ϳ3 hr when applied onto the SCN region. The phase-shifting effect was clearly dose dependent, with maximal phase-delay response at 100 M NMDA. The phase-shifting effects of NMDA have been shown to be similar to those of light, in that phase delays are elicited in early subjective night, phase advances later in the subjective night, with little phase shifting observed after treatment in the subjective day (Mintz et al., 1999 ). It appears that millimolar doses of NMDA are required for phase-shifting behavioral activity rhythms using in vivo microinjections of NMDA in hamsters (Mintz et al., 1999) . Doses in the millimolar range in our study induced double peaks and decreased firing activity in half of the slices. A similar disrupted pattern was seen after glutamate applications to rat SCN slices at CT 14 (Shirakawa and Moore, 1994) and might be similar to responses reported for glutamate applications at ZT 17 in vitro (Ding et al., 1994; Franken et al., 1999) .
We demonstrate that NPY blocks the phase-shifting effect of NMDA at ZT 14. This is similar to our previous results, in which NPY blocked the phase shifts induced by glutamate or light at ZT 14 and ZT 18 (Biello et al., 1997; Yannielli and Harrington, 2000) . It is interesting that novel wheel access, a treatment that produces phase shifts dependent on NPY (Biello et al., 1994) , was also able to block phase advances to light (Ralph and Mrosovsky, 1992) . However, our results are in apparent conflict with several previously published studies. In rat SCN, coapplication of NPY potentiates both advance and delay shifts induced by NMDA in vitro (Shibata et al., 1994) . It is unclear why this result is so different from ours, but it may be significant that these animals were housed under constant darkness for 24 -48 hr before experimentation. In a behavioral study, NPY did not alter phase delays Figure 5 . Effect of the Y5 and Y1 antagonists on NPY blockade of NMDA-induced phase delays. Shown are the means Ϯ SE of phase delays induced by NMDA (100 M) plus NPY (2 ng), in the presence or absence of 1 hr perfusion of Y1 antagonist BIBP 3226 (1 M) or Y5 antagonist RWJ 57926 (2 M). The Y5 antagonist significantly reversed the blockade of NPY on NMDA-induced phase delays, whereas the Y1 antagonist did not change the blocking effect of NPY on NMDA-induced phase delays. None of the antagonists interacted with the NMDA effect when applied alone, or NPY or control peak time values. Significant differences were as follows: NMDA alone, NMDA plus Y1 antagonist, NMDA plus Y5 antagonist, and NMDA plus NPY plus Y5 antagonist versus all the other treatments, including the Y1 and Y5 antagonists applied alone; *p Ͻ 0.05; ANOVA followed by Student-Newman-Keuls method. to light but did reduce light-induced phase advances (Weber and Rea, 1997) .
There are at least six known subtypes of neuropeptide Y receptor (for review, see Ingenhoven and Beck-Sickinger, 1999) . The Y2 receptor can be distinguished by its responsiveness to NPY3-36 (Grandt et al., 1996) , whereas [Leu 31 ,Pro 34 ]NPY has often been used as a Y1 receptor agonist (Fuhlendorff et al., 1990) , although it can also bind to the Y5 receptor (Ingenhoven and Beck-Sickinger, 1999 (Cabrele et al., 2000) . Also, a new Y5 receptor antagonist (RWJ 57926) has been developed recently and has been shown to bind selectively and potently to Y5 receptors in vitro, as well as to inhibit the ingestive behavior in rats . Our work using these compounds indicates that the Y5 receptor mediates the blocking effect of NPY on NMDA-induced phase shifts. Thus, the receptor by which NPY can induce phase advances during the subjective day [the Y2 receptor (Golombek et al., 1996; Huhman et al., 1996) ] is different from the receptor by which NPY presumably inhibits photic phase shifts during the subjective night. The rat SCN shows high levels of expression of the mRNAs encoding the Y1 and Y5 but not the Y2 or Y4 receptors (Larsen and Kristensen, 1998) . The higher levels of expression of the Y5 versus the Y2 receptor in the SCN might explain the much lower concentrations of NPY needed to block NMDA-induced phase shifts (ϳ0.02 M) (Fig. 3) versus those necessary for NPY-induced phase shifts in the subjective day (ϳ20 M) (Golombek et al., 1996) .
Our results indicate that NPY acts at some point at or beyond NMDA receptor response in the light-induced signal transduction cascade. One possibility is that photic and nonphotic signals could interact via effects on membrane potential. In general, glutamate is depolarizing (Meijer et al., 1993) , whereas NPY is hyperpolarizing (van den Pol et al., 1996; Hall et al., 1999) . NPY can activate a K ϩ -selective conductance in the SCN, and although the subjective day phase-shifting action of NPY does not depend on the action of NPY to increase K ϩ channel conductance (Hall et al., 1999) , it remains possible that effects of NPY on light-induced shifts are mediated via these changes in K ϩ conductance. Y5 agonists can induce inhibition of firing activity without affecting the phase of the activity rhythm (Harrington and Hoque, 1997; Cutler et al., 1998; Gribkoff et al., 1998) . These data suggest that the phase-shifting effect of NPY and the inhibition of light-induced phase shifts by NPY could be mediated by different mechanisms. It is interesting that serotonin and melatonin also appear to use a different receptor subtype for their subjective day phase-shifting effects on circadian rhythms than the subtype mediating inhibitory effects on either photic responses or electrical activity Liu et al., 1997; Pickard and Rea, 1998) .
NPY may alter NMDA response by effects on intracellular calcium levels. NPY induces a long-term depression in glutamatestimulated rises in intracellular calcium levels (van den Pol et al., 1996) . Both the Y1/Y5 and Y2 receptors were implicated in these effects, which were only seen concomitant with glutamatergic receptor activation. Serotonergic stimulation is associated with similar reductions in glutamate-induced calcium responses (Quintero and McMahon, 1999) and also with similar reductions of light-induced phase shifts Pickard and Rea, 1998; Weber et al., 1998) . Because activation of the Y5 receptor also leads to inhibition of cAMP accumulation (Gerald et al., 1996) , cAMP reduction could be a possible mechanism of action. Recent results have shown that inhibitors of protein kinase A can block glutamate-induced phase shifts in vitro in rats (Tischkau et al., 2000) , and in our laboratory, we have observed a similar result using hamsters (our unpublished results). This raises the possibility that NPY could inhibit cAMP accumulation and thus a step in the light-activated pathway.
NPY may ultimately work by changing gene expression; for example, altering levels of some recently identified circadian clock-related genes (for review, see Dunlap, 1999) . NPY might suppress light-induced gene expression and thus might negatively modulate light input. Preliminary results of our laboratory show that NPY has an inhibitory effect on light-induced per1 and per2 in vitro . During the subjective day, both NPY and novel wheel access [a stimulus associated with NPY (Biello et al., 1994; Janik and Mrosovsky, 1994) ] can decrease mper1 and mper2 levels in hamster SCN (Maywood et al., 1999; Fukuhara et al., 2000; Maywood and Hastings, 2000) . Because the phase-resetting action of NPY in the subjective day does not require de novo synthesis of clock proteins (Hall et al., 1999) and novel wheel access does not alter PER1 protein levels (Maywood et al., 1999) , it is probable that the action of NPY on levels of per gene mRNA in the subjective day is more closely related to the action of NPY in the subjective night and does not play a causal role in the subjective daytime resetting action of NPY. This is supported by the lack of subjective day resetting when mPer1 antisense was administered to the suprachiasmatic nucleus (Akiyama et al., 1999) . In summary, the effect of NPY through its Y5 receptor during the subjective night could be attributable to many possible mechanisms, including inhibition of the increased electrical activity elicited by light-glutamate-NMDA, inhibition of Ca 2ϩ rise, and effects on clock gene expression.
Under either natural or seminatural conditions, nocturnal rodents, including hamsters, sample light during brief periods to entrain their internal cycle to the external 24 hr cycle (DeCoursey, 1986; Pratt and Goldman, 1986 ). NPY appears to play a role in negatively modulating this fundamental response. NPY is seasonally regulated in some mammals (Ribelayga et al., 1998) and thus may alter circadian rhythm entrainment in a seasondependent manner. If verified in humans, the ability of NPY to modulate the circadian-clock responses to light may be of clinical importance. Pharmaceuticals that target NPY receptors are under development for use in humans as anti-obesity agents; these would be expected to also alter photic entrainment of circadian rhythms. It is important to note that the mechanism by which NPY blocks photic effects might be different from the mechanism by which NPY can phase shift the clock during the day. Additional studies should be directed toward understanding the underlying mechanism, as well as the functional relevance of these effects.
